Tucson startup looks to human trials for drug to treat lung inflammation
Aqualung Therapeutics, a Tucson-based drug startup headed by a University of Arizona pulmonologist, has won a major investment
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models ByACCESSWIRE Published February 1,
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer TUCSON, AZ / ACCESSWIRE / January
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor Tuesday,
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th
Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation
Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients LINK TO PRESS
Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation
Targets Protein Linked To Acute Respiratory Distress Syndrome Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation Andrew McConaghieandrew.mcconaghie@informa.com Executive Summary Acute